CDMO Capacity Crunch Persists in Cell and Gene Therapy Sector: Strategic Partnerships Crucial for Accelerating Innovation

August 17, 2026

Contract Pharma USA

Overview

The cell and gene therapy (CGT) sector faces a severe and persistent capacity crunch among Contract Development and Manufacturing Organizations (CDMOs), driven by soaring demand. This bottleneck significantly impedes CGT developers from transitioning therapies from clinical stages to commercial production, hindering timely patient access to novel treatments. Overcoming this challenge necessitates streamlined technology transfer and strengthened strategic partnerships with CDMOs, which are critical to accelerating innovation and scaling manufacturing capabilities.

In Depth

Key Findings

The cell and gene therapy (CGT) sector is currently grappling with a severe and persistent capacity crunch within Contract Development and Manufacturing Organizations (CDMOs). As an increasing number of innovative CGT products advance from clinical development to commercialization, the manufacturing bottleneck has become a critical industry-wide challenge. This shortage, particularly acute for gene delivery systems like Adeno-Associated Virus (AAV) and lentiviral vectors, as well as for GMP manufacturing of cell therapy products, is a major impediment to delivering new treatments to patients in urgent need.

Technical and Clinical Details

Manufacturing CGT products is inherently complex, highly individualized, and subject to stringent quality and regulatory requirements, demanding specialized expertise and state-of-the-art facilities. For instance, the production of viral vectors involves intricate steps such as viral amplification in specific cell lines, purification, concentration, and aseptic filling into vials. Autologous cell therapies, which are derived from an individual patient’s cells, present unique scale-up challenges due to the need for personalized processing for each patient. While CDMOs offer these specialized manufacturing services, their existing capacities are struggling to keep pace with the exponential demand. Reports indicate that securing CDMO capacity is particularly challenging for companies scaling from early-stage clinical trials to late-stage development and commercial production. The success rates of manufacturing batches in CGT are typically lower than those for conventional biopharmaceuticals, emphasizing the need for profound expertise and experience.

Background and Industry Context

Over the past few years, the number of FDA and EMA-approved CGT products has steadily grown, with a robust pipeline of therapies anticipated in the coming decade. Market projections for the CGT sector are exceptionally high, with some forecasts predicting the gene therapy market alone to reach tens of billions of dollars by the late 2020s. However, sustaining this projected growth requires a commensurate expansion of manufacturing infrastructure. Many small biotechnology companies and academic institutions lack the resources to build and operate their own large-scale manufacturing facilities, leading to a high reliance on CDMOs. This situation, while creating substantial business opportunities for CDMOs, has simultaneously resulted in the ‘capacity crunch,’ where existing CDMOs cannot meet the burgeoning demand. This issue extends beyond physical facility limitations to include a critical shortage of skilled personnel specialized in CGT manufacturing.

Strategic Significance and Outlook

Addressing the CDMO capacity crunch necessitates a multifaceted strategic approach. Firstly, existing CDMOs must make significant investments in constructing new manufacturing facilities and expanding current ones. Secondly, fostering early and strategic partnerships between CGT developers and CDMOs is crucial. This collaboration enables the integration of Design for Manufacturability (DfM) principles from the outset of development, reducing technology transfer risks and timelines. Furthermore, the adoption of standardized manufacturing platforms and advanced automation technologies will significantly enhance manufacturing efficiency and reduce costs. Governments and regulatory bodies can also play a pivotal role by introducing policies that support CGT manufacturing infrastructure development and streamline facility approval processes. Through these concerted efforts, the CGT industry is expected to build the necessary manufacturing capabilities to deliver innovative therapies to patients more rapidly, ultimately transforming the global healthcare landscape.

Source: https://www.contractpharma.com/the-cdmo-capacity-crunch-persists/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.